Sun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in women's health. This strategic move aims to bolster Sun Pharma's innovative medicines business and establish it as a top-tier player in biosimilars and women's health globally.